Imatinib Mesylate Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 50 mg, 100 mg, 400 mg
Reference Brands: Gleevec® (EU & US)
Category: Oncology Cancer Care
Imatinib Mesylate is available in Tablet and strengths such as 50 mg, 100 mg, 400 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Imatinib Mesylate is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Imatinib Mesylate can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Imatinib Mesylate is a targeted therapy used in oncology to treat chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GISTs), and other cancers. Available under the brand Gleevec® by Novartis and as generics, Imatinib is an essential tyrosine kinase inhibitor (TKI) used in cancer centers, hospitals, and oncology clinics. It blocks the action of abnormal proteins that contribute to cancer cell growth, making it crucial for effective cancer management. Available in oral tablets and generics, Imatinib Mesylate is widely sourced by B2B pharmaceutical wholesalers in the US and EU, ensuring reliable supply and GMP-compliant distribution for cancer treatment.
Frequently Asked Questions
Related Products
Atezolizumab
Strength:
1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details
Durvalumab
Strength:
120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details
Sunitinib
Strength:
12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers
